- SEK152.24m
- SEK114.41m
- SEK57.70m
- 50
- 19
- 28
- 20
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.76 | ||
| Price to Tang. Book | 3.91 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.64 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -21.43% | ||
| Return on Equity | -23.14% | ||
| Operating Margin | -32.84% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | 7.96 | 15.42 | 41.77 | 49.87 | 57.7 | 77.5 | 103 | 84.16% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
SenzaGen AB is a Sweden-based company, which specializes in immunology, technology and genomics. The Company markets, sells and performs the in vitro Genomic Allergen Rapid Detection (GARD) sensitization test through its own laboratory and through licensed Contract Research Organization (CROs). SenzaGen AB makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals people come in contact with in their daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The Company sells the tests in Sweden and the United States, and also sells through partners in several other countries. SenzaGen AB has a subsidiary in San Francisco, the United States.
Directors
- Carl Borrebaeck CHM (73)
- Peter Nahlstedt CEO (47)
- Henrik Johansson CSO (38)
- Marianne Olsson VFN (59)
- Maria Agemark VOP (46)
- Tina Dackemark Lawesson VPR (52)
- Anna Cherouvrier Hansson VBD (47)
- Mikael Wahlgren OTH (55)
- Anki Malmborg Hager DRC (55)
- Laura Chirica IND (52)
- Ann Gidner IND (54)
- Ian Kimber IND (70)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 25th, 2010
- Public Since
- September 21st, 2017
- No. of Employees
- 34
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
OMX Nordic Exchange Stockholm- Shares in Issue
- 29,504,026
- Address
- Medicon Village, LUND, 223 63
- Web
- https://senzagen.com/
- Phone
- +46 462756200
- Auditors
- HLB Auditoriet AB
Upcoming Events for SENZA
Similar to SENZA
2cureX AB
OMX Nordic Exchange Stockholm
Acousort AB
OMX Nordic Exchange Stockholm
Active Biotech AB publ
OMX Nordic Exchange Stockholm
Alligator Bioscience AB
OMX Nordic Exchange Stockholm
AlzeCure Pharma AB
OMX Nordic Exchange Stockholm
FAQ
As of Today at 23:09 UTC, shares in SenzaGen AB are trading at SEK5.16. This share price information is delayed by 15 minutes.
Shares in SenzaGen AB last closed at SEK5.16 and the price had moved by -18.87% over the past 365 days. In terms of relative price strength the SenzaGen AB share price has underperformed the FTSE Global All Cap Index by -20.9% over the past year.
There is no consensus recommendation for this security.
Find out moreSenzaGen AB does not currently pay a dividend.
SenzaGen AB does not currently pay a dividend.
SenzaGen AB does not currently pay a dividend.
To buy shares in SenzaGen AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of SEK5.16, shares in SenzaGen AB had a market capitalisation of SEK152.24m.
Here are the trading details for SenzaGen AB:
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: SENZA
Based on an overall assessment of its quality, value and momentum SenzaGen AB is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in SenzaGen AB is SEK14.50. That is 181.01% above the last closing price of SEK5.16.
Analysts covering SenzaGen AB currently have a consensus Earnings Per Share (EPS) forecast of -SEK0.17 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like SenzaGen AB. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -31.74%.
As of the last closing price of SEK5.16, shares in SenzaGen AB were trading -23.45% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The SenzaGen AB PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK5.16.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
SenzaGen AB's management team is headed by:
- Carl Borrebaeck - CHM
- Peter Nahlstedt - CEO
- Henrik Johansson - CSO
- Marianne Olsson - VFN
- Maria Agemark - VOP
- Tina Dackemark Lawesson - VPR
- Anna Cherouvrier Hansson - VBD
- Mikael Wahlgren - OTH
- Anki Malmborg Hager - DRC
- Laura Chirica - IND
- Ann Gidner - IND
- Ian Kimber - IND